Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Bcr-Abl fusion sequences do not induce immune responses in mice when administered in mouse polyomavirus based virus-like particles

V Hruskova, A Moravkova, K Babiarova, V Ludvikova, J Fric, V Vonka, J Forstova

Jazyk angličtina Země Řecko

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12008640

Mouse polyomavirus-like particles (MPyV-VLPs) carrying inside a fragment of the Bcr-Abl hybrid protein containing the epitope of chronic myeloid leukemia fusion region were prepared. A sequence encoding 171 amino acids covering Bcr-Abl breakpoint was fused to the C-terminal part of VP3 minor protein connecting it to the VP1 capsomeres. Chimeric particles, the Bcr-Abl VLPs, were tested for their ability to induce Bcr-Abl specific immune response in mice after their intranasal (i.n.) or intraperitoneal (i.p.) administration without any other adjuvants. Bcr-Abl VLPs induced strong anti-VP1 immune response in both i.n. and i.p. immunized mice. As expected, neither IgG nor IgM anti-Bcr-Abl specific antibodies were detected in the sera of immunized animals. Surprisingly, no specific CTL (cytotoxic T-lymphocyte) activity was proved using two different methods (in vitro cytotoxicity assay with CFSE-labeled target cells and highly sensitive cytotoxicity assay using MHC class I Bcr-Abl specific pentamers). In addition, no proliferative response of T-cells of i.n. immunized mice after in vitro restimulation with antigen-pulsed bone marrow-derived dendritic cells was observed. Taken together, Bcr-Abl breakpoint epitopes appeared to be weak immunogens and even MPyV-VLPs did not provide sufficient adjuvant ability to support induction of immune responses specific to Bcr-Abl fusion zone epitope.

Citace poskytuje Crossref.org

000      
03049naa a2200433 a 4500
001      
bmc12008640
003      
CZ-PrNML
005      
20141106100822.0
008      
120316s2009 gr eng||
009      
AR
024    __
$a 10.3892/ijo_00000441 $2 doi
035    __
$a (PubMed)19885546
040    __
$a ABA008 $b cze $d ABA008
041    0_
$a eng
044    __
$a gr
100    1_
$a Hrušková, Veronika $u Faculty of Science, Charles University in Prague, 128 44 Prague 2, Czech Republic. $7 xx0228115
245    10
$a Bcr-Abl fusion sequences do not induce immune responses in mice when administered in mouse polyomavirus based virus-like particles / $c V Hruskova, A Moravkova, K Babiarova, V Ludvikova, J Fric, V Vonka, J Forstova
520    9_
$a Mouse polyomavirus-like particles (MPyV-VLPs) carrying inside a fragment of the Bcr-Abl hybrid protein containing the epitope of chronic myeloid leukemia fusion region were prepared. A sequence encoding 171 amino acids covering Bcr-Abl breakpoint was fused to the C-terminal part of VP3 minor protein connecting it to the VP1 capsomeres. Chimeric particles, the Bcr-Abl VLPs, were tested for their ability to induce Bcr-Abl specific immune response in mice after their intranasal (i.n.) or intraperitoneal (i.p.) administration without any other adjuvants. Bcr-Abl VLPs induced strong anti-VP1 immune response in both i.n. and i.p. immunized mice. As expected, neither IgG nor IgM anti-Bcr-Abl specific antibodies were detected in the sera of immunized animals. Surprisingly, no specific CTL (cytotoxic T-lymphocyte) activity was proved using two different methods (in vitro cytotoxicity assay with CFSE-labeled target cells and highly sensitive cytotoxicity assay using MHC class I Bcr-Abl specific pentamers). In addition, no proliferative response of T-cells of i.n. immunized mice after in vitro restimulation with antigen-pulsed bone marrow-derived dendritic cells was observed. Taken together, Bcr-Abl breakpoint epitopes appeared to be weak immunogens and even MPyV-VLPs did not provide sufficient adjuvant ability to support induction of immune responses specific to Bcr-Abl fusion zone epitope.
590    __
$a bohemika - dle Pubmed
650    02
$a zvířata $7 D000818
650    02
$a antigeny virové $x imunologie $7 D000956
650    02
$a western blotting $7 D015153
650    02
$a cytotoxicita imunologická $7 D003602
650    02
$a epitopy $x imunologie $7 D000939
650    02
$a fluorescenční protilátková technika $7 D005455
650    02
$a bcr-abl fúzní proteiny $x imunologie $7 D016044
650    02
$a lidé $7 D006801
650    02
$a chronická myeloidní leukemie $x imunologie $7 D015464
650    02
$a myši $7 D051379
650    02
$a imunoelektronová mikroskopie $7 D016253
650    02
$a Polyomavirus $x imunologie $7 D011120
650    02
$a rekombinantní proteiny $x imunologie $7 D011994
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Morávková, A.
700    1_
$a Babiarová, Katarína $7 xx0118496
700    1_
$a Ludvíková, Viera, $d 1954- $7 xx0078797
700    1_
$a Frič, Jan $7 xx0106155
700    1_
$a Vonka, Vladimír, $d 1930- $7 jk01150642
700    1_
$a Forstová, Jitka, $d 1944- $7 xx0057861
773    0_
$t International Journal of Oncology $p Int J Oncol $g Roč. 35, č. 6 (2009), s. 1247-1256 $w MED00002350 $x 0946-1965
773    0_
$p Int J Oncol $g 35(6):1247-56, 2009 Dec
910    __
$a ABA008 $b x $y 4 $z 0
990    __
$a 20120319124600 $b ABA008
991    __
$a 20141106100831 $b ABA008
999    __
$a ok $b bmc $g 901985 $s 765535
BAS    __
$a 3
BMC    __
$a 2009 $b 35 $c 6 $d 1247-1256 $m International journal of oncology $x MED00002350
LZP    __
$a 2012-1Q10/

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé